In the wake of scientists and developers leaving no stone unturned to manufacture a potential vaccine to cure the novel Coronavirus, an accurate and cheaper pandemic test was developed by Indian scientists.
CRISPR Feluda' COVID-19 test developed by the CSIR-Institute of Genomics and Integrative Biology (IGIB) and the TATA Group could be a game-changer as the testing is cheaper and accurate.
The scientists said that the new pandemic tests give a more accurate result when compared to the antigen test. The test priced at Rs 500 is expected to deliver the result in 45 minutes.
The scientists developed the CRISPR Feluda' COVID-19 test in a way that the SARS-CoV-2 type of virus could be differentiated from the other types of Coronaviruses.
The Drug Controller General of India (DCGI) gave its nod for the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Feluda test for commercial purposes.
It is believed that the CRISPR Feluda test posses a sensitivity of 96 percent and 98 percent of specificity in detecting the COVID-19 virus. If the virus is detected, Faluda changes its colour.
CRISPR Feluda' COVID-19 test developed by the CSIR-Institute of Genomics and Integrative Biology (IGIB) and the TATA Group could be a game-changer as the testing is cheaper and accurate.
The scientists said that the new pandemic tests give a more accurate result when compared to the antigen test. The test priced at Rs 500 is expected to deliver the result in 45 minutes.
The scientists developed the CRISPR Feluda' COVID-19 test in a way that the SARS-CoV-2 type of virus could be differentiated from the other types of Coronaviruses.
The Drug Controller General of India (DCGI) gave its nod for the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Feluda test for commercial purposes.
It is believed that the CRISPR Feluda test posses a sensitivity of 96 percent and 98 percent of specificity in detecting the COVID-19 virus. If the virus is detected, Faluda changes its colour.